Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00153062
Other study ID # 9.159
Secondary ID
Status Completed
Phase Phase 4
First received September 9, 2005
Last updated April 22, 2014
Start date August 2003

Study information

Verified date April 2014
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority Argentina: Ministry of HealthAustralia: Dept of Health and Ageing Therapeutic Goods AdminAustria: Agency for Health and Food SafetyBelgium: Federal Agency for Medicinal and Health ProductsBrazil: National Health Surveillance AgencyCanada: Health CanadaChina: Ministry of HealthDenmark: National Board of HealthFinland: Finnish Medicines AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Ministry of HealthGreece: Ministry of Health and WelfareHong Kong: Department of HealthIndia: Ministry of HealthIreland: Irish Medicines BoardIsrael: Israeli Health Ministry Pharmaceutical AdministrationItaly: Ministry of HealthJapan: Pharmaceuticals and Medical Devices AgencyKorea: Food and Drug AdministrationMalaysia: Ministry of HealthMexico: Ministry of HealthNetherlands: Dutch Health Care InspectorateNorway: Norwegian Medicines AgencyPortugal: National Pharmacy and Medicines InstituteRussia: Pharmacological Committee, Ministry of HealthSingapore: Health Sciences AuthoritySouth Africa: Department of HealthSpain: Ministry of HealthSweden: The National Board of Health and WelfareTaiwan: Department of HealthThailand: Ministry of Public HealthTurkey: Ministry of Health Central Ethics CommitteeUkraine: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.


Recruitment information / eligibility

Status Completed
Enrollment 20332
Est. completion date
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion criteria:

Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors:

- Diabetes mellitus

- Hypertension (systolic BP ¿ 140 or diastolic BP ¿ 90)

- Smoker at time of qualifying stroke

- Obesity (BMI>30; BMI=weight (kg)/[height (m)]2)

- Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke)

- End-organ-damage (retinopathy, LVH, or microalbuminuria)

- Hyperlipidemia

Exclusion criteria:

hemorrhagic stroke (must be ruled out by imaging);unable to give informed consent; known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding ;hyperkalemia;uncorrected volume or sodium depletion; pre-stroke history of dementia;modified Rankin score greater than 4;qualifying stroke induced by surgical or cardiovascular procedure;uncontrolled hypertension at entry above 180/110 mmHg (goal BPs are lower); SBP 120 mmHg or less for hospitalized patients; currently taking an ARB and not able or willing to switch to alternative; required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors; syndrome of asthma, rhinitis and nasal polyps;scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed);unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial; history of thrombocytopenia or neutropenia.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Aggrenox
25mg aspirin, 200 mg dipyridamole
Aggrenox
25mg aspirin, 200 mg dipyridamole
Clopidogrel placebo
placebo
Clopidogrel placebo
placebo
Micardis
80 mg micardis
Micardis
80 mg micardis
Aggrenox placebo
placebo
Aggrenox placebo
placebo
Clopidogrel
75 mg clopidogrel
Clopidogrel
75 mg clopidogrel
Micardis placebo
placebo
Micardis placebo
placebo

Locations

Country Name City State
Argentina 9.159.1331 Boehringer Ingelheim Investigational Site Capital Federal
Argentina 9.159.1333 Boehringer Ingelheim Investigational Site Capital Federal
Argentina 9.159.1334 Boehringer Ingelheim Investigational Site Capital Federal
Argentina 9.159.1335 Boehringer Ingelheim Investigational Site Capital Federal
Argentina 9.159.1336 Boehringer Ingelheim Investigational Site Capital Federal
Argentina 9.159.1332 Boehringer Ingelheim Investigational Site Rosario, Sta. Fe
Argentina 9.159.1342 Boehringer Ingelheim Investigational Site Santa Fe
Australia 9.159.2451 Boehringer Ingelheim Investigational Site Bedford Park South Australia
Australia 9.159.2443 Boehringer Ingelheim Investigational Site Box Hill Victoria
Australia 9.159.2444 Boehringer Ingelheim Investigational Site Gosford New South Wales
Australia 9.159.2450 Boehringer Ingelheim Investigational Site Herston Queensland
Australia 9.159.2447 Boehringer Ingelheim Investigational Site Melbourne Victoria
Australia 9.159.2449 Boehringer Ingelheim Investigational Site New Lambton New South Wales
Australia 9.159.2445 Boehringer Ingelheim Investigational Site Parkville Victoria
Australia 9.159.2452 Boehringer Ingelheim Investigational Site Southport Queensland
Australia 9.159.2446 Boehringer Ingelheim Investigational Site West Heidelberg Victoria
Australia 9.159.2448 Boehringer Ingelheim Investigational Site Westmead New South Wales
Austria 9.159.1515 Boehringer Ingelheim Investigational Site Graz
Austria 9.159.1519 Boehringer Ingelheim Investigational Site Graz
Austria 9.159.1517 Boehringer Ingelheim Investigational Site Innsbruck
Austria 9.159.1516 Boehringer Ingelheim Investigational Site Linz
Austria 9.159.1518 Boehringer Ingelheim Investigational Site Ma.Gugging/Klosterneuburg
Austria 9.159.1520 Boehringer Ingelheim Investigational Site St. Pölten
Austria 9.159.1521 Boehringer Ingelheim Investigational Site Wien
Belgium 9.159.1553 Boehringer Ingelheim Investigational Site Aalst
Belgium 9.159.1543 Boehringer Ingelheim Investigational Site Anderlecht
Belgium 9.159.1552 Boehringer Ingelheim Investigational Site Antwerpen
Belgium 9.159.1546 Boehringer Ingelheim Investigational Site Bonheiden
Belgium 9.159.1547 Boehringer Ingelheim Investigational Site Brugge
Belgium 9.159.1550 Boehringer Ingelheim Investigational Site Bruxelles
Belgium 9.159.1549 Boehringer Ingelheim Investigational Site Hasselt
Belgium 9.159.1555 Boehringer Ingelheim Investigational Site Kortrijk
Belgium 9.159.1554 Boehringer Ingelheim Investigational Site La Louvière
Belgium 9.159.1544 Boehringer Ingelheim Investigational Site Leuven
Belgium 9.159.1548 Boehringer Ingelheim Investigational Site Montegnée
Belgium 9.159.1556 Boehringer Ingelheim Investigational Site Ottignies
Belgium 9.159.1545 Boehringer Ingelheim Investigational Site Wilrijk
Belgium 9.159.1551 Boehringer Ingelheim Investigational Site Yvoir
Brazil 9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos Salvador
Brazil 9.159.2853 Boehringer Ingelheim Investigational Site São Paulo
Canada 9.159.1393 Boehringer Ingelheim Investigational Site Barrie Ontario
Canada 9.159.1397 Foothills Medical Centre Calgary Alberta
Canada 9.159.1392 Boehringer Ingelheim Investigational Site Corner Brook Newfoundland and Labrador
Canada 9.159.1382 Boehringer Ingelheim Investigational Site Edmonton Alberta
Canada 9.159.1359 Boehringer Ingelheim Investigational Site Greenfield Park Quebec
Canada 9.159.1395 Boehringer Ingelheim Investigational Site Hamilton Ontario
Canada 9.159.1370 Boehringer Ingelheim Investigational Site Kamloops British Columbia
Canada 9.159.1360 Boehringer Ingelheim Investigational Site Kingston Ontario
Canada 9.159.1390 Boehringer Ingelheim Investigational Site Lethbridge Alberta
Canada 9.159.1367 Boehringer Ingelheim Investigational Site London Ontario
Canada 9.159.1384 Boehringer Ingelheim Investigational Site London Ontario
Canada 9.159.1380 Boehringer Ingelheim Investigational Site Mississauga Ontario
Canada 9.159.1361 Boehringer Ingelheim Investigational Site Montreal Quebec
Canada 9.159.1362 Boehringer Ingelheim Investigational Site Montreal Quebec
Canada 9.159.1371 Boehringer Ingelheim Investigational Site Montreal Quebec
Canada 9.159.1374 Boehringer Ingelheim Investigational Site Montreal Quebec
Canada 9.159.1388 Boehringer Ingelheim Investigational Site Montreal Quebec
Canada 9.159.1368 Boehringer Ingelheim Investigational Site New Westminster British Columbia
Canada 9.159.1378 Boehringer Ingelheim Investigational Site Ottawa Ontario
Canada 9.159.1381 Ottawa Hospital General Campus Ottawa Ontario
Canada 9.159.1376 Boehringer Ingelheim Investigational Site Penticton British Columbia
Canada 9.159.1372 Boehringer Ingelheim Investigational Site Quebec City Quebec
Canada 9.159.1389 Boehringer Ingelheim Investigational Site Regina Saskatchewan
Canada 9.159.1366 Boehringer Ingelheim Investigational Site Richmond Hill Ontario
Canada 9.159.1358 Boehringer Ingelheim Investigational Site Saguenay Quebec
Canada 9.159.1356 Boehringer Ingelheim Investigational Site Saint John New Brunswick
Canada 9.159.1396 Boehringer Ingelheim Investigational Site Saskatoon Saskatchewan
Canada 9.159.1365 Boehringer Ingelheim Investigational Site Scarborough Ontario
Canada 9.159.1375 Boehringer Ingelheim Investigational Site Scarborough Ontario
Canada 9.159.1364 Boehringer Ingelheim Investigational Site St. Jerome Quebec
Canada 9.159.1385 Boehringer Ingelheim Investigational Site St. John's Newfoundland and Labrador
Canada 9.159.1373 Boehringer Ingelheim Investigational Site Sydney Nova Scotia
Canada 9.159.1391 Boehringer Ingelheim Investigational Site Tecumseh Ontario
Canada 9.159.1369 Boehringer Ingelheim Investigational Site Thunder Bay Ontario
Canada 9.159.1357 Boehringer Ingelheim Investigational Site Toronto Ontario
Canada 9.159.1379 Boehringer Ingelheim Investigational Site Toronto Ontario
Canada 9.159.1383 Boehringer Ingelheim Investigational Site Toronto Ontario
Canada 9.159.1387 Boehringer Ingelheim Investigational Site Vancouver British Columbia
Canada 9.159.1377 Boehringer Ingelheim Investigational Site Victoria British Columbia
Canada 9.159.1363 Boehringer Ingelheim Investigational Site Windsor Ontario
Canada 9.159.1355 Boehringer Ingelheim Investigational Site Winnipeg Manitoba
Canada 9.159.1394 Boehringer Ingelheim Investigational Site Winnipeg Manitoba
China 9.159.2490 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2491 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2492 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2493 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2494 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2495 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2496 Boehringer Ingelheim Investigational Site Beijing
China 9.159.2503 Boehringer Ingelheim Investigational Site Changchun, Jilin Province
China 9.159.2500 Boehringer Ingelheim Investigational Site Changsha, Hunan Province
China 9.159.2513 Boehringer Ingelheim Investigational Site Chengdu, Sichuan Province
China 9.159.2512 Boehringer Ingelheim Investigational Site Chongqing
China 9.159.2509 Boehringer Ingelheim Investigational Site Guangzhou
China 9.159.2518 Boehringer Ingelheim Investigational Site Guangzhou
China 9.159.2521 Boehringer Ingelheim Investigational Site Guangzhou
China 9.159.2507 Boehringer Ingelheim Investigational Site Guangzhou, Guangdong Province
China 9.159.2510 Boehringer Ingelheim Investigational Site Guangzhou, Guangdong Province
China 9.159.2502 Boehringer Ingelheim Investigational Site Hangzhou, Zhejiang Province
China 9.159.2504 Boehringer Ingelheim Investigational Site Harbin, Heilongjiang Province
China 9.159.2505 Boehringer Ingelheim Investigational Site Jinan, Shandong Province
China 9.159.2506 Boehringer Ingelheim Investigational Site Jinan, Shangdong Province
China 9.159.2517 Boehringer Ingelheim Investigational Site Nanjing, Jiangsu Province
China 9.159.2519 Boehringer Ingelheim Investigational Site Nanjing, Jiangsu Province
China 9.159.2520 Boehringer Ingelheim Investigational Site Nanjing, Jiangsu Province
China 9.159.2483 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2484 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2485 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2486 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2487 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2488 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2489 Boehringer Ingelheim Investigational Site Shanghai
China 9.159.2516 Boehringer Ingelheim Investigational Site Suzhou, Jiangsu Province
China 9.159.2497 Boehringer Ingelheim Investigational Site Tianjin
China 9.159.2501 Boehringer Ingelheim Investigational Site Wenzhou, Zhejiang Province
China 9.159.2498 Boehringer Ingelheim Investigational Site Wuhan, Hubei Province
China 9.159.2499 Boehringer Ingelheim Investigational Site Wuhan, Hubei Province
China 9.159.2511 Boehringer Ingelheim Investigational Site Xian
China 9.159.2514 Boehringer Ingelheim Investigational Site Xian, Shanxi
China 9.159.2515 Boehringer Ingelheim Investigational Site Xian, Shanxi Province
Denmark 9.159.1636 Boehringer Ingelheim Investigational Site Aarhuc C
Denmark 9.159.1635 Boehringer Ingelheim Investigational Site Aarhus C
Denmark 9.159.1639 Boehringer Ingelheim Investigational Site Esbjerg
Denmark 9.159.1634 Boehringer Ingelheim Investigational Site Frederiksberg
Denmark 9.159.1637 Boehringer Ingelheim Investigational Site Glostrup
Denmark 9.159.1640 Boehringer Ingelheim Investigational Site Hellerup
Denmark 9.159.1638 Boehringer Ingelheim Investigational Site Hvidovre
Denmark 9.159.1633 Boehringer Ingelheim Investigational Site København NV
Denmark 9.159.1631 Boehringer Ingelheim Investigational Site København Ø
Denmark 9.159.1632 Boehringer Ingelheim Investigational Site Odense
El Salvador 9.159.2181 Boehringer Ingelheim Investigational Site Oviedo
Finland 9.159.1655 Boehringer Ingelheim Investigational Site Helsinki
Finland 9.159.1658 Boehringer Ingelheim Investigational Site Kuopio
Finland 9.159.1659 Boehringer Ingelheim Investigational Site Lappeenranta
Finland 9.159.1656 Boehringer Ingelheim Investigational Site Oulu
Finland 9.159.1657 Boehringer Ingelheim Investigational Site Seinäjoki
France 9.159.1680 Boehringer Ingelheim Investigational Site Lille cedex
France 9.159.1683 Boehringer Ingelheim Investigational Site Limoges cedex 1
France 9.159.1681 Boehringer Ingelheim Investigational Site Marseille cedex 05
France 9.159.1679 Boehringer Ingelheim Investigational Site Nancy
France 9.159.1685 Boehringer Ingelheim Investigational Site Paris cedex 19
France 9.159.1682 Boehringer Ingelheim Investigational Site Poitiers cedex
France 9.159.1684 Boehringer Ingelheim Investigational Site Tours cedex 9
Germany 9.159.1713 Boehringer Ingelheim Investigational Site Bad Neustadt/Saale
Germany 9.159.1736 Boehringer Ingelheim Investigational Site Berlin
Germany 9.159.1732 Boehringer Ingelheim Investigational Site Braunschweig
Germany 9.159.1726 Boehringer Ingelheim Investigational Site Cloppenburg
Germany 9.159.1723 Boehringer Ingelheim Investigational Site Dresden
Germany 9.159.1728 Boehringer Ingelheim Investigational Site Düsseldorf
Germany 9.159.1707 Boehringer Ingelheim Investigational Site Essen
Germany 9.159.1738 Boehringer Ingelheim Investigational Site Freiburg
Germany 9.159.1720 Boehringer Ingelheim Investigational Site Gießen
Germany 9.159.1722 Boehringer Ingelheim Investigational Site Hamburg
Germany 9.159.1739 Boehringer Ingelheim Investigational Site Hamburg
Germany 9.159.1724 Boehringer Ingelheim Investigational Site Heidelberg
Germany 9.159.1734 Boehringer Ingelheim Investigational Site Jena
Germany 9.159.1730 Boehringer Ingelheim Investigational Site Kaiserslautern
Germany 9.159.1737 Boehringer Ingelheim Investigational Site Köln
Germany 9.159.1717 Boehringer Ingelheim Investigational Site Leipzig
Germany 9.159.1735 Boehringer Ingelheim Investigational Site Ludwigshafen am Rhein
Germany 9.159.1712 Boehringer Ingelheim Investigational Site Magdeburg
Germany 9.159.1710 Boehringer Ingelheim Investigational Site Mainz
Germany 9.159.1709 Boehringer Ingelheim Investigational Site Minden
Germany 9.159.1716 Boehringer Ingelheim Investigational Site Mönchengladbach
Germany 9.159.1718 Boehringer Ingelheim Investigational Site München
Germany 9.159.1725 Boehringer Ingelheim Investigational Site München
Germany 9.159.1729 Boehringer Ingelheim Investigational Site München
Germany 9.159.1727 Boehringer Ingelheim Investigational Site Münster
Germany 9.159.1711 Boehringer Ingelheim Investigational Site Nürnberg
Germany 9.159.1719 Boehringer Ingelheim Investigational Site Regensburg
Germany 9.159.1731 Boehringer Ingelheim Investigational Site Remscheid
Germany 9.159.1708 Boehringer Ingelheim Investigational Site Rostock
Germany 9.159.1715 Boehringer Ingelheim Investigational Site Saarbrücken
Germany 9.159.1714 Boehringer Ingelheim Investigational Site Siegen
Germany 9.159.1733 Boehringer Ingelheim Investigational Site Stuttgart
Germany 9.159.1721 Boehringer Ingelheim Investigational Site Weimar
Greece 9.159.1826 Boehringer Ingelheim Investigational Site Alexandroupolis
Greece 9.159.1819 Boehringer Ingelheim Investigational Site Athens
Greece 9.159.1820 Boehringer Ingelheim Investigational Site Athens
Greece 9.159.1821 Boehringer Ingelheim Investigational Site Athens
Greece 9.159.1825 Boehringer Ingelheim Investigational Site Ioannina
Greece 9.159.1824 Boehringer Ingelheim Investigational Site Patras
Hong Kong 9.159.2713 Boehringer Ingelheim Investigational Site Hong KoNG
Hong Kong 9.159.2714 Boehringer Ingelheim Investigational Site Hong Kong
India 9.159.2605 Boehringer Ingelheim Investigational Site Annamalainagar
India 9.159.2603 Boehringer Ingelheim Investigational Site Bangalore
India 9.159.2620 Boehringer Ingelheim Investigational Site Bangalore
India 9.159.2616 Boehringer Ingelheim Investigational Site Bikaner
India 9.159.2618 Boehringer Ingelheim Investigational Site Calicut
India 9.159.2604 Boehringer Ingelheim Investigational Site Chennai
India 9.159.2619 Boehringer Ingelheim Investigational Site Chennai
India 9.159.2625 Boehringer Ingelheim Investigational Site Chennai
India 9.159.2606 Boehringer Ingelheim Investigational Site Cochin
India 9.159.2607 Boehringer Ingelheim Investigational Site Hyderabad
India 9.159.2624 Boehringer Ingelheim Investigational Site Hyderabad
India 9.159.2630 Boehringer Ingelheim Investigational Site Hyderabad
India 9.159.2632 Boehringer Ingelheim Investigational Site Hyderabad
India 9.159.2610 Boehringer Ingelheim Investigational Site Indore
India 9.159.2615 Boehringer Ingelheim Investigational Site Jaipur
India 9.159.2617 Boehringer Ingelheim Investigational Site Jaipur
India 9.159.2612 Boehringer Ingelheim Investigational Site Jodhpur
India 9.159.2621 Boehringer Ingelheim Investigational Site Kottayam
India 9.159.2613 Boehringer Ingelheim Investigational Site Lucknow
India 9.159.2614 Boehringer Ingelheim Investigational Site Ludhiana
India 9.159.2611 Boehringer Ingelheim Investigational Site Mumbai
India 9.159.2628 Boehringer Ingelheim Investigational Site New Delhi
India 9.159.2629 Boehringer Ingelheim Investigational Site New Delhi
India 9.159.2623 Boehringer Ingelheim Investigational Site Patiala
India 9.159.2609 Boehringer Ingelheim Investigational Site Pune
India 9.159.2622 Boehringer Ingelheim Investigational Site Pune
India 9.159.2627 Boehringer Ingelheim Investigational Site Secunderabad
India 9.159.2626 Boehringer Ingelheim Investigational Site Trichy
India 9.159.2631 Boehringer Ingelheim Investigational Site Visakhapatnam
India 9.159.2608 Boehringer Ingelheim Investigational Site Wardha
Ireland 9.159.1851 Boehringer Ingelheim Investigational Site Cork
Ireland 9.159.1852 Boehringer Ingelheim Investigational Site Dublin 7
Israel 9.159.2729 Barzilai Medical Center Ashkelon
Israel 9.159.2721 Neurology Unit Haifa
Israel 9.159.2724 Rambam Medical Center, Tel-Aviv Medical Haifa
Israel 9.159.2723 Boehringer Ingelheim Investigational Site Israel
Israel 9.159.2727 Western Galilee Hospital Naharia
Israel 9.159.2722 Neurology Unit Petach Tikva
Israel 9.159.2726 Sheba Medical Center Tel Hashomer
Israel 9.159.2725 Tel Aviv Medical Center Tel-Aviv
Italy 9.159.1875 Università degli Studi di Ancona Ancona
Italy 9.159.1882 Ospedale Brotzu Cagliari
Italy 9.159.1883 Azienda Ospedaliera S. Anna Como
Italy 9.159.1871 Azienda Ospedaliera "Careggi" Firenze
Italy 9.159.1869 Università degli Studi di Genova Genova
Italy 9.159.1870 ASL No. 5 di Jesi Jesi (ancona)
Italy 9.159.1865 Ospedale Regionale "S. Salvatore" L'aquila
Italy 9.159.1866 Ospedale S. Raffaele Milano
Italy 9.159.1873 Istituto Scientifico "S. Luca" Milano
Italy 9.159.1884 Ospedale S. Carlo Borromeo" Milano
Italy 9.159.1868 Ospedale "S. Maria di Loreto Mare" Napoli
Italy 9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario Padova
Italy 9.159.1874 Ospedale Civico - ARNAS Palermo
Italy 9.159.1872 Neuromed IRCCS Pozzilli (IS)
Italy 9.159.1879 Policlinico S. Andrea Roma
Italy 9.159.1881 Università "La Sapienza" Roma
Italy 9.159.1877 Azienda Ospedaliera Umberto I Siracusa
Italy 9.159.1878 Azienda Ospedaliera "Santo Maria" Terni
Italy 9.159.1864 Azienda Ospedaliera "S. Giovanni Battista" Torino
Italy 9.159.1863 Ospedale di Cattinara Trieste
Italy 9.159.1867 Presidio Ospedaliero G.Jazzolino Vibo Valentia
Italy 9.159.1880 Ospedale Civile Vicenza
Japan 9.159.2964 Boehringer Ingelheim Investigational Site Adachi-ku, Tokyo
Japan 9.159.2958 Boehringer Ingelheim Investigational Site Akashi, Hyogo
Japan 9.159.2970 Boehringer Ingelheim Investigational Site Akashi, Hyogo
Japan 9.159.2965 Boehringer Ingelheim Investigational Site Ako, Hyogo
Japan 9.159.2968 Boehringer Ingelheim Investigational Site Aoba-ku, Yokohama, Kanagawa
Japan 9.159.2951 Boehringer Ingelheim Investigational Site Azumino, Nagano
Japan 9.159.2959 Boehringer Ingelheim Investigational Site Chitose, Hokkaido
Japan 9.159.2944 Boehringer Ingelheim Investigational Site Chuo-ku, Kobe, Hyogo
Japan 9.159.2947 Boehringer Ingelheim Investigational Site Chuo-Ku, Sapporo, Hokkaido
Japan 9.159.2954 Boehringer Ingelheim Investigational Site Fushimi-ku, Kyoto, Kyoto
Japan 9.159.2942 Boehringer Ingelheim Investigational Site Habikino, Osaka
Japan 9.159.2948 Boehringer Ingelheim Investigational Site Higashi-ku, Sapporo, Hokkaido
Japan 9.159.2957 Boehringer Ingelheim Investigational Site Higashi-osaka, Osaka
Japan 9.159.2940 Boehringer Ingelheim Investigational Site Higashinari-ku, Osaka, Osaka
Japan 9.159.2973 Boehringer Ingelheim Investigational Site Higashiyodogawa-ku, Osaka, Osaka
Japan 9.159.2949 Boehringer Ingelheim Investigational Site Hitachinaka, Ibaraki
Japan 9.159.2953 Boehringer Ingelheim Investigational Site Iida, Nagano
Japan 9.159.2943 Boehringer Ingelheim Investigational Site Izumisano, Osaka
Japan 9.159.2963 Boehringer Ingelheim Investigational Site Jyonan-ku, Fukuoka, Fukuoka
Japan 9.159.2933 Boehringer Ingelheim Investigational Site Kasama, Ibaraki
Japan 9.159.2955 Boehringer Ingelheim Investigational Site Kasuga, Fukuoka
Japan 9.159.2938 Boehringer Ingelheim Investigational Site Kita-ku, Osaka, Osaka
Japan 9.159.2967 Boehringer Ingelheim Investigational Site Koriyama, Fukushima
Japan 9.159.2969 Boehringer Ingelheim Investigational Site Kushiro, Hokkaido
Japan 9.159.2952 Boehringer Ingelheim Investigational Site Matsumoto, Nagano
Japan 9.159.2961 Boehringer Ingelheim Investigational Site Midori-ku, Yokohama, Kanagawa
Japan 9.159.2934 Boehringer Ingelheim Investigational Site Moriya, Ibaraki
Japan 9.159.2971 Boehringer Ingelheim Investigational Site Musashino, Tokyo
Japan 9.159.2962 Boehringer Ingelheim Investigational Site Nakagawa-ku, Nagoya, Aichi
Japan 9.159.2939 Boehringer Ingelheim Investigational Site Nishi-yodogawa-ku, Osaka, Osaka
Japan 9.159.2956 Boehringer Ingelheim Investigational Site Ohnojo, Fukuoka
Japan 9.159.2941 Boehringer Ingelheim Investigational Site Sakai-ku, Sakai, Osaka
Japan 9.159.2945 Boehringer Ingelheim Investigational Site Sawara-ku, Fukuoka, Fukuoka
Japan 9.159.2937 Boehringer Ingelheim Investigational Site Shimogyo-ku, Kyoto, Kyoto
Japan 9.159.2966 Boehringer Ingelheim Investigational Site Shiroishi, Miyagi
Japan 9.159.2936 Boehringer Ingelheim Investigational Site Suwa, Nagano
Japan 9.159.2946 Boehringer Ingelheim Investigational Site Takikawa, Hokkaido
Japan 9.159.2935 Boehringer Ingelheim Investigational Site Tatebayashi, Gunma
Japan 9.159.2950 Boehringer Ingelheim Investigational Site Tsuchiura, Ibaraki
Japan 9.159.2972 Boehringer Ingelheim Investigational Site Yao, Osaka
Korea, Republic of 9.159.1593 Boehringer Ingelheim Investigational Site Gwangju
Korea, Republic of 9.159.1595 Boehringer Ingelheim Investigational Site Incheon
Korea, Republic of 9.159.1592 Boehringer Ingelheim Investigational Site Kyunggi-do
Korea, Republic of 9.159.1591 Boehringer Ingelheim Investigational Site Seoul
Korea, Republic of 9.159.1594 Boehringer Ingelheim Investigational Site Seoul
Korea, Republic of 9.159.1597 Boehringer Ingelheim Investigational Site Seoul
Korea, Republic of 9.159.1596 Boehringer Ingelheim Investigational Site Suwon
Malaysia 9.159.2707 Boehringer Ingelheim Investigational Site Kelantan Darul Naim
Malaysia 9.159.2706 Boehringer Ingelheim Investigational Site Kuala Lumpur
Mexico 9.159.2765 Boehringer Ingelheim Investigational Site Metepec
Netherlands 9.159.1960 Jeroen Bosch Ziekenhuis 's-Hertogenbosch
Netherlands 9.159.1945 Medisch Centrum Alkmaar Alkmaar
Netherlands 9.159.1963 Polikliniek Neurologie Assen
Netherlands 9.159.1949 Ziekenhuis Gooi-Noord Blaricum
Netherlands 9.159.1962 Locatie Molengracht Breda
Netherlands 9.159.1950 HagaZiekenhuis Den Haag
Netherlands 9.159.1959 Catharina Ziekenhuis Eindhoven
Netherlands 9.159.1946 Scheper Ziekenhuis Emmen
Netherlands 9.159.1958 Medisch Spectrum Twente Enschede
Netherlands 9.159.1943 Umcg Groningen
Netherlands 9.159.1961 Lokatie Van Swieten Groningen
Netherlands 9.159.1953 Atrium Medisch Centrum Heerlen
Netherlands 9.159.1955 Elkerliek Ziekenhuis Helmond
Netherlands 9.159.1951 Ziekenhuisgroep Twente Hengelo
Netherlands 9.159.1948 Medisch Centrum Leeuwarden Leeuwarden
Netherlands 9.159.1952 Rijnland Ziekenhuis Leiderdorp
Netherlands 9.159.1947 Sint Antonius Ziekenhuis Nieuwegein
Netherlands 9.159.1964 Canisius-Wilhelmina ziekenhuis Nijmegen
Netherlands 9.159.1956 TweeSteden Ziekenhuis Tilburg Tilburg
Netherlands 9.159.1957 Sint Elisabeth Ziekenhuis Tilburg
Netherlands 9.159.1944 Máxima Medisch Centrum Veldhoven
Netherlands 9.159.1954 St. Jans Gasthuis Weert
Norway 9.159.2029 Boehringer Ingelheim Investigational Site Bergen
Norway 9.159.2028 Boehringer Ingelheim Investigational Site Oslo
Norway 9.159.2027 Boehringer Ingelheim Investigational Site Trondheim
Portugal 9.159.2040 Hospital Fernando Fonseca Amadora
Portugal 9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE Coimbra
Portugal 9.159.2041 Centro Hospitalar de Lisboa Norte Lisboa
Portugal 9.159.2042 Centro Hospitalar do Porto Porto
Russian Federation 9.159.2114 Boehringer Ingelheim Investigational Site Ekaterinburg
Russian Federation 9.159.2102 Boehringer Ingelheim Investigational Site Kazan
Russian Federation 9.159.2117 Boehringer Ingelheim Investigational Site Kemerovo
Russian Federation 9.159.2107 Boehringer Ingelheim Investigational Site Kirov
Russian Federation 9.159.2116 Boehringer Ingelheim Investigational Site Krasnoyarsk
Russian Federation 9.159.2079 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2080 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2081 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2082 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2083 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2084 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2085 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2087 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2088 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2089 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2090 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2091 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2092 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2093 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2095 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2098 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2101 Boehringer Ingelheim Investigational Site Moscow
Russian Federation 9.159.2105 Boehringer Ingelheim Investigational Site Nizhnyi Novgorod
Russian Federation 9.159.2115 Boehringer Ingelheim Investigational Site Novosibirsk
Russian Federation 9.159.2119 Boehringer Ingelheim Investigational Site Omsk
Russian Federation 9.159.2111 Boehringer Ingelheim Investigational Site Orel
Russian Federation 9.159.2106 Boehringer Ingelheim Investigational Site Rostov-na-Donu
Russian Federation 9.159.2108 Boehringer Ingelheim Investigational Site Samara
Russian Federation 9.159.2109 Boehringer Ingelheim Investigational Site Saratov
Russian Federation 9.159.2110 Boehringer Ingelheim Investigational Site Saratov
Russian Federation 9.159.2118 Boehringer Ingelheim Investigational Site Seversk
Russian Federation 9.159.2086 Boehringer Ingelheim Investigational Site Smolensk
Russian Federation 9.159.2094 Boehringer Ingelheim Investigational Site St. Petersburg
Russian Federation 9.159.2097 Boehringer Ingelheim Investigational Site St. Petersburg
Russian Federation 9.159.2099 Boehringer Ingelheim Investigational Site St. Petersburg
Russian Federation 9.159.2100 Boehringer Ingelheim Investigational Site St. Petersburg
Russian Federation 9.159.2120 Boehringer Ingelheim Investigational Site Ufa
Russian Federation 9.159.2112 Boehringer Ingelheim Investigational Site Volgograd
Russian Federation 9.159.2113 Boehringer Ingelheim Investigational Site Volgograd
Russian Federation 9.159.2104 Boehringer Ingelheim Investigational Site Voronezh
Russian Federation 9.159.2103 Boehringer Ingelheim Investigational Site Yaroslavl
Singapore 9.159.2703 Boehringer Ingelheim Investigational Site Singapore
Singapore 9.159.2704 Boehringer Ingelheim Investigational Site Singapore
Singapore 9.159.2705 Boehringer Ingelheim Investigational Site Singapore
South Africa 9.159.2060 Boehringer Ingelheim Investigational Site Bloemfontein
South Africa 9.159.2056 Boehringer Ingelheim Investigational Site Cape Town
South Africa 9.159.2057 Boehringer Ingelheim Investigational Site Durban
South Africa 9.159.2055 Boehringer Ingelheim Investigational Site Johannesburg
South Africa 9.159.2061 Boehringer Ingelheim Investigational Site Johannesburg
South Africa 9.159.2058 Boehringer Ingelheim Investigational Site Pretoria
South Africa 9.159.2059 Boehringer Ingelheim Investigational Site Sunninghill
Spain 9.159.2179 Boehringer Ingelheim Investigational Site Alicante
Spain 9.159.2177 Boehringer Ingelheim Investigational Site Barcelona
Spain 9.159.2178 Boehringer Ingelheim Investigational Site Hospitalet de Llobregat (Barcelona)
Spain 9.159.2175 Boehringer Ingelheim Investigational Site Madrid
Spain 9.159.2176 Boehringer Ingelheim Investigational Site Madrid
Spain 9.159.2180 Boehringer Ingelheim Investigational Site Pamplona
Sweden 9.159.2223 Boehringer Ingelheim Investigational Site Borås
Sweden 9.159.2209 Boehringer Ingelheim Investigational Site Eskilstuna
Sweden 9.159.2204 Boehringer Ingelheim Investigational Site Göteborg
Sweden 9.159.2205 Boehringer Ingelheim Investigational Site Göteborg
Sweden 9.159.2728 Neurology Unit Holon
Sweden 9.159.2210 Boehringer Ingelheim Investigational Site Jönköping
Sweden 9.159.2206 Boehringer Ingelheim Investigational Site Lund
Sweden 9.159.2211 Boehringer Ingelheim Investigational Site Mora
Sweden 9.159.2208 Boehringer Ingelheim Investigational Site Örebro
Sweden 9.159.2216 Boehringer Ingelheim Investigational Site Skellefteå
Sweden 9.159.2215 Boehringer Ingelheim Investigational Site Skövde
Sweden 9.159.2203 Boehringer Ingelheim Investigational Site Stockholm
Sweden 9.159.2212 Boehringer Ingelheim Investigational Site Stockholm
Sweden 9.159.2213 Boehringer Ingelheim Investigational Site Stockholm
Sweden 9.159.2222 Boehringer Ingelheim Investigational Site Stockholm
Sweden 9.159.2225 Boehringer Ingelheim Investigational Site Stockholm
Sweden 9.159.2207 Boehringer Ingelheim Investigational Site Umeå
Sweden 9.159.2214 Boehringer Ingelheim Investigational Site Värnamo
Sweden 9.159.2224 Boehringer Ingelheim Investigational Site Västervik
Taiwan 9.159.2250 Boehringer Ingelheim Investigational Site Kaohsiung
Taiwan 9.159.2253 Boehringer Ingelheim Investigational Site Kaohsiung
Taiwan 9.159.2248 Boehringer Ingelheim Investigational Site Taichung
Taiwan 9.159.2249 Boehringer Ingelheim Investigational Site Taichung
Taiwan 9.159.2251 Boehringer Ingelheim Investigational Site Tainan
Taiwan 9.159.2244 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2245 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2246 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2247 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2252 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2254 Boehringer Ingelheim Investigational Site Taipei
Taiwan 9.159.2243 Boehringer Ingelheim Investigational Site Taoyuan
Thailand 9.159.2797 Boehringer Ingelheim Investigational Site Bangkok
Thailand 9.159.2798 Boehringer Ingelheim Investigational Site Bangkok
Thailand 9.159.2799 Boehringer Ingelheim Investigational Site Bangkok
Thailand 9.159.2800 Boehringer Ingelheim Investigational Site Bangkok
Thailand 9.159.2801 Boehringer Ingelheim Investigational Site Chiang Mai
Turkey 9.159.2830 Boehringer Ingelheim Investigational Site Ankara
Turkey 9.159.2829 Boehringer Ingelheim Investigational Site Antalya
Turkey 9.159.2831 Boehringer Ingelheim Investigational Site Bursa
Turkey 9.159.2827 Boehringer Ingelheim Investigational Site Eskisehir
Turkey 9.159.2825 Boehringer Ingelheim Investigational Site Istanbul
Turkey 9.159.2826 Boehringer Ingelheim Investigational Site Istanbul
Turkey 9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D. Izmir
Ukraine 9.159.2387 Boehringer Ingelheim Investigational Site Dnepropetrovsk
Ukraine 9.159.2384 Boehringer Ingelheim Investigational Site Kharkiv
Ukraine 9.159.2385 Boehringer Ingelheim Investigational Site Kharkiv
Ukraine 9.159.2386 Boehringer Ingelheim Investigational Site Kharkiv
Ukraine 9.159.2392 Boehringer Ingelheim Investigational Site Kharkiv
Ukraine 9.159.2379 Boehringer Ingelheim Investigational Site Kyiv
Ukraine 9.159.2380 Boehringer Ingelheim Investigational Site Kyiv
Ukraine 9.159.2382 Boehringer Ingelheim Investigational Site Kyiv
Ukraine 9.159.2389 Boehringer Ingelheim Investigational Site Odesa
Ukraine 9.159.2390 Boehringer Ingelheim Investigational Site Odesa
Ukraine 9.159.2391 Boehringer Ingelheim Investigational Site Vinnytzya
Ukraine 9.159.2388 Boehringer Ingelheim Investigational Site Zaporizhzhya
United Kingdom 9.159.2304 Boehringer Ingelheim Investigational Site Belfast
United Kingdom 9.159.2297 Boehringer Ingelheim Investigational Site Birmingham
United Kingdom 9.159.2299 Boehringer Ingelheim Investigational Site Bournemouth
United Kingdom 9.159.2301 Boehringer Ingelheim Investigational Site Bristol
United Kingdom 9.159.2298 Boehringer Ingelheim Investigational Site Dundee
United Kingdom 9.159.2307 Boehringer Ingelheim Investigational Site Exeter
United Kingdom 9.159.2296 Boehringer Ingelheim Investigational Site Glasgow
United Kingdom 9.159.2300 Boehringer Ingelheim Investigational Site Glasgow
United Kingdom 9.159.2287 Boehringer Ingelheim Investigational Site Harrow
United Kingdom 9.159.2303 Boehringer Ingelheim Investigational Site Henshingham, Whitehaven
United Kingdom 9.159.2308 Boehringer Ingelheim Investigational Site Leicester
United Kingdom 9.159.2295 Boehringer Ingelheim Investigational Site Liverpool
United Kingdom 9.159.2286 Boehringer Ingelheim Investigational Site London
United Kingdom 9.159.2293 Boehringer Ingelheim Investigational Site London
United Kingdom 9.159.2294 Boehringer Ingelheim Investigational Site London
United Kingdom 9.159.2305 Boehringer Ingelheim Investigational Site Mansfield
United Kingdom 9.159.2290 Boehringer Ingelheim Investigational Site Newcastle Upon Tyne
United Kingdom 9.159.2288 Boehringer Ingelheim Investigational Site North Shields
United Kingdom 9.159.2285 Boehringer Ingelheim Investigational Site Northampton
United Kingdom 9.159.2284 Boehringer Ingelheim Investigational Site Nottingham
United Kingdom 9.159.2283 Boehringer Ingelheim Investigational Site Poole
United Kingdom 9.159.2302 Boehringer Ingelheim Investigational Site Rotherham
United Kingdom 9.159.2292 Boehringer Ingelheim Investigational Site Sheffield
United Kingdom 9.159.2289 Boehringer Ingelheim Investigational Site Southampton
United Kingdom 9.159.2306 Boehringer Ingelheim Investigational Site Stoke on Trent
United Kingdom 9.159.2291 Boehringer Ingelheim Investigational Site Sunderland
United States 9.159.1171 Boehringer Ingelheim Investigational Site Abington Pennsylvania
United States 9.159.1159 Boehringer Ingelheim Investigational Site Akron Ohio
United States 9.159.1086 Boehringer Ingelheim Investigational Site Albany New York
United States 9.159.1170 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
United States 9.159.1210 Boehringer Ingelheim Investigational Site Allentown Pennsylvania
United States 9.159.1214 Boehringer Ingelheim Investigational Site Allentown Pennsylvania
United States 9.159.1099 Boehringer Ingelheim Investigational Site Asheville North Carolina
United States 9.159.1071 Boehringer Ingelheim Investigational Site Atlanta Georgia
United States 9.159.1079 Boehringer Ingelheim Investigational Site Augusta Georgia
United States 9.159.1024 Boehringer Ingelheim Investigational Site Baltimore Maryland
United States 9.159.1055 Boehringer Ingelheim Investigational Site Baltimore Maryland
United States 9.159.1139 Boehringer Ingelheim Investigational Site Baltimore Maryland
United States 9.159.1106 Boehringer Ingelheim Investigational Site Baton Rouge Louisiana
United States 9.159.1057 Boehringer Ingelheim Investigational Site Bay Pines Florida
United States 9.159.1040 Boehringer Ingelheim Investigational Site Berkeley California
United States 9.159.1101 Boehringer Ingelheim Investigational Site Birmingham Alabama
United States 9.159.1215 Boehringer Ingelheim Investigational Site Bismarck North Dakota
United States 9.159.1217 Boehringer Ingelheim Investigational Site Boca Raton Florida
United States 9.159.1189 Boehringer Ingelheim Investigational Site Boise Idaho
United States 9.159.1031 Boehringer Ingelheim Investigational Site Boston Massachusetts
United States 9.159.1066 Boehringer Ingelheim Investigational Site Boston Massachusetts
United States 9.159.1104 Boehringer Ingelheim Investigational Site Boston Massachusetts
United States 9.159.1166 Boehringer Ingelheim Investigational Site Boston Massachusetts
United States 9.159.1003 Boehringer Ingelheim Investigational Site Bountiful Utah
United States 9.159.1096 Boehringer Ingelheim Investigational Site Bradenton Florida
United States 9.159.1006 Boehringer Ingelheim Investigational Site Bristol Tennessee
United States 9.159.1121 Boehringer Ingelheim Investigational Site Bronx New York
United States 9.159.1130 Boehringer Ingelheim Investigational Site Bronx New York
United States 9.159.1017 Boehringer Ingelheim Investigational Site Brooklyn New York
United States 9.159.1064 Boehringer Ingelheim Investigational Site Brooklyn New York
United States 9.159.1186 Boehringer Ingelheim Investigational Site Brooklyn New York
United States 9.159.1219 Boehringer Ingelheim Investigational Site Brownwood Texas
United States 9.159.1151 Boehringer Ingelheim Investigational Site Buffalo New York
United States 9.159.1204 Boehringer Ingelheim Investigational Site Camden New Jersey
United States 9.159.1085 Boehringer Ingelheim Investigational Site Canton Ohio
United States 9.159.1180 Boehringer Ingelheim Investigational Site Carmichael California
United States 9.159.1027 Boehringer Ingelheim Investigational Site Cedar Rapids Iowa
United States 9.159.1046 Boehringer Ingelheim Investigational Site Chapel Hill North Carolina
United States 9.159.1211 Boehringer Ingelheim Investigational Site Charleston West Virginia
United States 9.159.1026 University of Illinois Chicago Illinois
United States 9.159.1033 Boehringer Ingelheim Investigational Site Chicago Illinois
United States 9.159.1060 Boehringer Ingelheim Investigational Site Chicago Illinois
United States 9.159.1032 Boehringer Ingelheim Investigational Site Cincinnati Ohio
United States 9.159.1144 Boehringer Ingelheim Investigational Site Clearwater Florida
United States 9.159.1025 Boehringer Ingelheim Investigational Site Cleveland Ohio
United States 9.159.1177 Boehringer Ingelheim Investigational Site Cleveland Ohio
United States 9.159.1140 Boehringer Ingelheim Investigational Site Columbia South Carolina
United States 9.159.1008 Boehringer Ingelheim Investigational Site Columbus Ohio
United States 9.159.1141 Boehringer Ingelheim Investigational Site Columbus Ohio
United States 9.159.1181 Boehringer Ingelheim Investigational Site Columbus Georgia
United States 9.159.1155 Boehringer Ingelheim Investigational Site Dallas Texas
United States 9.159.1197 Boehringer Ingelheim Investigational Site Dallas Texas
United States 9.159.1038 Boehringer Ingelheim Investigational Site Danbury Connecticut
United States 9.159.1138 Boehringer Ingelheim Investigational Site Decatur Georgia
United States 9.159.1118 Boehringer Ingelheim Investigational Site Denver Colorado
United States 9.159.1119 Boehringer Ingelheim Investigational Site Des Moines Iowa
United States 9.159.1187 Boehringer Ingelheim Investigational Site Des Moines Iowa
United States 9.159.1019 Boehringer Ingelheim Investigational Site Detroit Michigan
United States 9.159.1048 Boehringer Ingelheim Investigational Site Detroit Michigan
United States 9.159.1089 Boehringer Ingelheim Investigational Site Detroit Michigan
United States 9.159.1088 Boehringer Ingelheim Investigational Site Duluth Minnesota
United States 9.159.1158 Boehringer Ingelheim Investigational Site Duluth Minnesota
United States 9.159.1094 Boehringer Ingelheim Investigational Site Durham North Carolina
United States 9.159.1078 Boehringer Ingelheim Investigational Site East Lansing Michigan
United States 9.159.1203 Boehringer Ingelheim Investigational Site Edison New Jersey
United States 9.159.1156 Boehringer Ingelheim Investigational Site Elkhart Indiana
United States 9.159.1045 Boehringer Ingelheim Investigational Site Englewood Colorado
United States 9.159.1200 Boehringer Ingelheim Investigational Site Erie Pennsylvania
United States 9.159.1196 Boehringer Ingelheim Investigational Site Fairfield Connecticut
United States 9.159.1152 Boehringer Ingelheim Investigational Site Fargo North Dakota
United States 9.159.1184 Boehringer Ingelheim Investigational Site Fayetteville Arkansas
United States 9.159.1005 Boehringer Ingelheim Investigational Site Fort Smith Arkansas
United States 9.159.1007 Boehringer Ingelheim Investigational Site Ft. Lauderdale Florida
United States 9.159.1084 Boehringer Ingelheim Investigational Site Golden Valley Minnesota
United States 9.159.1143 Boehringer Ingelheim Investigational Site Grand Rapids Michigan
United States 9.159.1146 Boehringer Ingelheim Investigational Site Great Falls Montana
United States 9.159.1043 Boehringer Ingelheim Investigational Site Greensburg Pennsylvania
United States 9.159.1207 Boehringer Ingelheim Investigational Site Greenville South Carolina
United States 9.159.1018 Boehringer Ingelheim Investigational Site Hartford Connecticut
United States 9.159.1164 Boehringer Ingelheim Investigational Site Hershey Pennsylvania
United States 9.159.1012 Boehringer Ingelheim Investigational Site High Point North Carolina
United States 9.159.1020 Boehringer Ingelheim Investigational Site Houston Texas
United States 9.159.1023 Boehringer Ingelheim Investigational Site Houston Texas
United States 9.159.1082 Boehringer Ingelheim Investigational Site Houston Texas
United States 9.159.1160 Boehringer Ingelheim Investigational Site Houston Texas
United States 9.159.1173 Boehringer Ingelheim Investigational Site Huntsville Alabama
United States 9.159.1059 Boehringer Ingelheim Investigational Site Iowa City Iowa
United States 9.159.1114 Boehringer Ingelheim Investigational Site Irvine California
United States 9.159.1190 Boehringer Ingelheim Investigational Site Jacksonville Florida
United States 9.159.1136 Boehringer Ingelheim Investigational Site Jonesboro Arkansas
United States 9.159.1102 Boehringer Ingelheim Investigational Site Kalamazoo Michigan
United States 9.159.1090 Boehringer Ingelheim Investigational Site Kansas City Kansas
United States 9.159.1128 St. Luke's Hospital MABSI Research Kansas City Missouri
United States 9.159.1154 Boehringer Ingelheim Investigational Site Knoxville Tennessee
United States 9.159.1202 Boehringer Ingelheim Investigational Site Laguna Hills California
United States 9.159.1175 Boehringer Ingelheim Investigational Site Lancaster Pennsylvania
United States 9.159.1127 Boehringer Ingelheim Investigational Site Las Vegas Nevada
United States 9.159.1172 Boehringer Ingelheim Investigational Site Lees Summit Missouri
United States 9.159.1129 Central Baptis Hospital Lexington Kentucky
United States 9.159.1131 Boehringer Ingelheim Investigational Site Lexington Kentucky
United States 9.159.1206 Boehringer Ingelheim Investigational Site Lexington Kentucky
United States 9.159.1212 Boehringer Ingelheim Investigational Site Lexington Kentucky
United States 9.159.1062 Boehringer Ingelheim Investigational Site Little Rock Arkansas
United States 9.159.1036 Boehringer Ingelheim Investigational Site Los Angeles California
United States 9.159.1052 Boehringer Ingelheim Investigational Site Los Angeles California
United States 9.159.1100 Boehringer Ingelheim Investigational Site Los Angeles California
United States 9.159.1111 Boehringer Ingelheim Investigational Site Los Angeles California
United States 9.159.1165 Boehringer Ingelheim Investigational Site Los Angeles California
United States 9.159.1091 Boehringer Ingelheim Investigational Site Louisville Kentucky
United States 9.159.1147 Boehringer Ingelheim Investigational Site Louisville Kentucky
United States 9.159.1042 Neurology Consultants of Burlington County Lumberton New Jersey
United States 9.159.1076 North Shore University Hospital Manasset New York
United States 9.159.1194 Boehringer Ingelheim Investigational Site Marrero Louisiana
United States 9.159.1030 Boehringer Ingelheim Investigational Site Marshfield Wisconsin
United States 9.159.1044 Boehringer Ingelheim Investigational Site Maywood Illinois
United States 9.159.1213 Boehringer Ingelheim Investigational Site Memphis Tennessee
United States 9.159.1117 Boehringer Ingelheim Investigational Site Milwaukee Wisconsin
United States 9.159.1037 Boehringer Ingelheim Investigational Site Mineola New York
United States 9.159.1097 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
United States 9.159.1113 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
United States 9.159.1058 Boehringer Ingelheim Investigational Site Mobile Alabama
United States 9.159.1087 Boehringer Ingelheim Investigational Site Montgomery Alabama
United States 9.159.1035 Boehringer Ingelheim Investigational Site Morgantown West Virginia
United States 9.159.1075 Boehringer Ingelheim Investigational Site Nashville Tennessee
United States 9.159.1209 Boehringer Ingelheim Investigational Site New Brunswick New Jersey
United States 9.159.1220 Boehringer Ingelheim Investigational Site New Hyde Park New York
United States 9.159.1083 Boehringer Ingelheim Investigational Site New Orleans Louisiana
United States 9.159.1001 Boehringer Ingelheim Investigational Site New York New York
United States 9.159.1116 Boehringer Ingelheim Investigational Site New York New York
United States 9.159.1142 Saint Luke's-Roosevelt Hospital New York New York
United States 9.159.1080 Boehringer Ingelheim Investigational Site Newark Delaware
United States 9.159.1125 Boehringer Ingelheim Investigational Site Newark New Jersey
United States 9.159.1077 Boehringer Ingelheim Investigational Site Newport News Virginia
United States 9.159.1081 Boehringer Ingelheim Investigational Site Northport Alabama
United States 9.159.1150 Boehringer Ingelheim Investigational Site Ocala Florida
United States 9.159.1134 Boehringer Ingelheim Investigational Site Oceanside California
United States 9.159.1199 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma
United States 9.159.1201 Boehringer Ingelheim Investigational Site Omaha Nebraska
United States 9.159.1002 Boehringer Ingelheim Investigational Site Palo Alto California
United States 9.159.1054 Boehringer Ingelheim Investigational Site Palos Heights Illinois
United States 9.159.1153 Boehringer Ingelheim Investigational Site Panama City Florida
United States 9.159.1068 Boehringer Ingelheim Investigational Site Park Ridge Illinois
United States 9.159.1178 Boehringer Ingelheim Investigational Site Peoria Illinois
United States 9.159.1016 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
United States 9.159.1056 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
United States 9.159.1074 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
United States 9.159.1022 Boehringer Ingelheim Investigational Site Phoenix Arizona
United States 9.159.1133 Boehringer Ingelheim Investigational Site Phoenix Arizona
United States 9.159.1149 Boehringer Ingelheim Investigational Site Phoenix Arizona
United States 9.159.1112 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
United States 9.159.1041 Boehringer Ingelheim Investigational Site Plantation Florida
United States 9.159.1072 Boehringer Ingelheim Investigational Site Port Charlotte Florida
United States 9.159.1010 Boehringer Ingelheim Investigational Site Portland Oregon
United States 9.159.1123 Boehringer Ingelheim Investigational Site Providence Rhode Island
United States 9.159.1108 Boehringer Ingelheim Investigational Site Redding California
United States 9.159.1188 Boehringer Ingelheim Investigational Site Reno Nevada
United States 9.159.1021 Boehringer Ingelheim Investigational Site Richmond Virginia
United States 9.159.1095 Boehringer Ingelheim Investigational Site Ridgewood New Jersey
United States 9.159.1070 Boehringer Ingelheim Investigational Site Rome Georgia
United States 9.159.1013 Boehringer Ingelheim Investigational Site Sacramento California
United States 9.159.1198 Boehringer Ingelheim Investigational Site Sacramento California
United States 9.159.1011 Boehringer Ingelheim Investigational Site Saginaw Michigan
United States 9.159.1174 Boehringer Ingelheim Investigational Site Saint Louis Missouri
United States 9.159.1061 Boehringer Ingelheim Investigational Site Salem Virginia
United States 9.159.1047 Boehringer Ingelheim Investigational Site San Antonio Texas
United States 9.159.1029 Boehringer Ingelheim Investigational Site San Diego California
United States 9.159.1185 Boehringer Ingelheim Investigational Site San Francisco California
United States 9.159.1218 Boehringer Ingelheim Investigational Site San Jose California
United States 9.159.1179 Boehringer Ingelheim Investigational Site Santa Rosa California
United States 9.159.1063 Boehringer Ingelheim Investigational Site Sarasota Florida
United States 9.159.1107 Boehringer Ingelheim Investigational Site Savannah Georgia
United States 9.159.1126 Boehringer Ingelheim Investigational Site Schenectady New York
United States 9.159.1014 Boehringer Ingelheim Investigational Site Seattle Washington
United States 9.159.1195 Boehringer Ingelheim Investigational Site Shreveport Louisiana
United States 9.159.1092 Boehringer Ingelheim Investigational Site South Bend Indiana
United States 9.159.1192 Boehringer Ingelheim Investigational Site South Weymouth Massachusetts
United States 9.159.1132 Boehringer Ingelheim Investigational Site Southfield Michigan
United States 9.159.1004 Boehringer Ingelheim Investigational Site Spartanberg South Carolina
United States 9.159.1145 Boehringer Ingelheim Investigational Site Spokane Washington
United States 9.159.1009 Boehringer Ingelheim Investigational Site Springfield Missouri
United States 9.159.1182 Boehringer Ingelheim Investigational Site St. Louis Missouri
United States 9.159.1191 Boehringer Ingelheim Investigational Site St. Louis Missouri
United States 9.159.1163 Boehringer Ingelheim Investigational Site Stony Brook New York
United States 9.159.1162 Boehringer Ingelheim Investigational Site Sylmar California
United States 9.159.1208 Boehringer Ingelheim Investigational Site Tampa Florida
United States 9.159.1053 Boehringer Ingelheim Investigational Site Toledo Ohio
United States 9.159.1169 Boehringer Ingelheim Investigational Site Tonawanda New York
United States 9.159.1183 Boehringer Ingelheim Investigational Site Torrance California
United States 9.159.1137 Boehringer Ingelheim Investigational Site Tucson Arizona
United States 9.159.1069 Boehringer Ingelheim Investigational Site Tyler Texas
United States 9.159.1148 Boehringer Ingelheim Investigational Site Upland Pennsylvania
United States 9.159.1049 Boehringer Ingelheim Investigational Site Vero Beach Florida
United States 9.159.1205 Boehringer Ingelheim Investigational Site Walnut Creek California
United States 9.159.1120 Boehringer Ingelheim Investigational Site Washington District of Columbia
United States 9.159.1216 Boehringer Ingelheim Investigational Site Washington District of Columbia
United States 9.159.1135 Boehringer Ingelheim Investigational Site Waterloo Iowa
United States 9.159.1098 Community Healthcare Clinic Westhill Medical Specialists Wausau Wisconsin
United States 9.159.1176 Boehringer Ingelheim Investigational Site West Palm Beach Florida
United States 9.159.1065 Boehringer Ingelheim Investigational Site White Plains New York
United States 9.159.1115 Wilmington North Carolina
United States 9.159.1051 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina
United States 9.159.1110 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina
United States 9.159.1039 Boehringer Ingelheim Investigational Site Worchester Massachusetts
United States 9.159.1122 Boehringer Ingelheim Investigational Site Youngstown Ohio

Sponsors (3)

Lead Sponsor Collaborator
Boehringer Ingelheim Bayer, GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  China,  Denmark,  El Salvador,  Finland,  France,  Germany,  Greece,  Hong Kong,  India,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Malaysia,  Mexico,  Netherlands,  Norway,  Portugal,  Russian Federation,  Singapore,  South Africa,  Spain,  Sweden,  Taiwan,  Thailand,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) time since randomization; follow-up period is 1.5 to 4.4 years
Primary Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only) time since randomization; follow-up period is 1.5 to 4.4 years
Secondary Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only) Number of patients with any of stroke, myocardial infarction, vascular death time since randomization; follow-up period is 1.5 to 4.4 years
Secondary Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only) Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure time since randomization; follow-up period is 1.5 to 4.4 years
Secondary Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only) Randomization to final patient contact
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A

External Links